VENTYX BIOSCIENCES PRESENTS NEW 52-WEEK RESULTS FROM THE PHASE 2 TRIAL OF VTX002 (TAMUZIMOD) IN ULCERATIVE COLITIS AT UEG WEEK 2024

Reuters · 10/15 12:00

Please log in to view news